We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+10.05%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$206M
AUM Growth
+$19.9M
Cap. Flow
-$6.78M
Cap. Flow %
-3.3%
Top 10 Hldgs %
45.09%
Holding
85
New
12
Increased
15
Reduced
25
Closed
10

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$11.1M
2
STXS icon
Stereotaxis
STXS
+$8.18M
3
AKBA icon
Akebia Therapeutics
AKBA
+$6.64M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$4.93M
5
LMNX
Luminex Corp
LMNX
+$4.14M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$12.2M
2
ONC
BeOne Medicines Ltd
ONC
+$7.32M
3
ARGX icon
argenx
ARGX
+$2.81M
4
VYGR icon
Voyager Therapeutics
VYGR
+$2.61M
5
ASND icon
Ascendis Pharma A/S
ASND
+$2.55M

Sector Composition

Rank Sector Weight
1 Healthcare 92.6%
2 Miscellaneous 6.59%
3 Financials 0.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$20.9M 10.19%
181,537
-114,463
-39% -$12.2M
SAGE
2
DELISTED
Sage Therapeutics
SAGE
$15.1M 7.37%
94,000
+65,200
+226% +$11.1M
STXS icon
3
Stereotaxis
STXS
$145M
$9.1M 4.43%
13,680,554
+12,307,692
+896% +$8.18M
BPMC
4
DELISTED
Blueprint Medicines
BPMC
$8.13M 3.96%
88,691
-12,000
-12% -$1.03M
ATRC icon
5
AtriCure
ATRC
$2.47B
$7.99M 3.88%
389,145
– –
NXTM
6
DELISTED
NxStage Medical Inc.
NXTM
$7.61M 3.7%
306,119
+90,000
+42% +$2.19M
AERI
7
DELISTED
Aerie Pharmaceuticals
AERI
$7.2M 3.5%
132,770
+16,000
+14% +$895K
AKBA icon
8
Akebia Therapeutics
AKBA
$243M
$5.82M 2.83%
610,738
+475,000
+350% +$6.64M
DXCM icon
9
DexCom
DXCM
$34.3B
$5.56M 2.71%
300,000
-32,000
-10% -$473K
ASND icon
10
Ascendis Pharma A/S
ASND
$16.3B
$5.18M 2.52%
79,245
-45,394
-36% -$2.55M
ALDR
11
DELISTED
Alder Biopharmaceuticals
ALDR
$5.03M 2.45%
396,013
+50,000
+14% +$723K
ARNA
12
DELISTED
Arena Pharmaceuticals Inc
ARNA
$5.01M 2.44%
+126,742
New +$4.93M
LMNX
13
DELISTED
Luminex Corp
LMNX
$4.79M 2.33%
227,500
+202,500
+810% +$4.14M
ARGX icon
14
argenx
ARGX
$64B
$4.68M 2.27%
58,130
-37,266
-39% -$2.81M
BCRX icon
15
BioCryst Pharmaceuticals
BCRX
$2.51B
$4.65M 2.26%
974,652
-218,576
-18% -$1.12M
NBIX icon
16
Neurocrine Biosciences
NBIX
$15.7B
$4.52M 2.2%
54,508
– –
CBAY
17
DELISTED
Cymabay Therapeutics
CBAY
$4.21M 2.05%
323,843
-37,321
-10% -$464K
IMMU
18
DELISTED
Immunomedics Inc
IMMU
$4.1M 2%
280,900
-23,100
-8% -$377K
LKFT
19
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$3.95M 1.92%
39,609
– –
ZGNX
20
DELISTED
Zogenix, Inc.
ZGNX
$3.77M 1.84%
94,264
-39,883
-30% -$1.58M
VBIV
21
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$3.49M 1.7%
33,267
– –
ACHN
22
DELISTED
Achillion Pharmaceuticals
ACHN
$3.22M 1.57%
868,272
-80,000
-8% -$262K
RIGL icon
23
Rigel Pharmaceuticals
RIGL
$868M
$3.19M 1.55%
90,193
-8,155
-8% -$326K
PODD icon
24
Insulet
PODD
$10.1B
$2.82M 1.37%
32,484
– –
IBB icon
25
iShares Biotechnology ETF
IBB
$10.5B
$2.79M 1.36%
26,100
– –
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, DAFNA Capital Management held 85 positions worth $206M, up 11% from $186M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

DAFNA Capital Management withdrew a net $6.78M in Q1 2018, closing 10 positions and reducing 25 holdings. Its most notable exit was Voyager Therapeutics, an estimated $2.61M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, DAFNA Capital Management opened a new position in Arena Pharmaceuticals Inc worth $5.01M.

  • DAFNA Capital Management's largest Q1 2018 buy was Arena Pharmaceuticals Inc: 126,742 shares worth $5.01M.
  • DAFNA Capital Management added most to Sage Therapeutics in Q1 2018, an estimated $11.1M increase.
  • DAFNA Capital Management's biggest Q1 2018 reduction was Loxo Oncology, Inc, cutting an estimated $12.2M.
  • DAFNA Capital Management fully exited Voyager Therapeutics in Q1 2018, selling an estimated $2.61M.
  • DAFNA Capital Management's ten largest holdings make up 45% of its $206M portfolio in Q1 2018.
  • DAFNA Capital Management opened 12 new positions and closed 10 in Q1 2018.
  • DAFNA Capital Management's portfolio value rose 11% quarter-over-quarter to $206M.

Based on DAFNA Capital Management's 13F filing for Q1 2018, filed 15 May 2018.